Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Clin Rheumatol. 2018 Jan;24(1):1–5. doi: 10.1097/RHU.0000000000000613

Table 2.

Baseline Characteristics of the Black and White Participants in the Knee Pain Trial

Black
(n=285)
White
(n=785)
p
value
Black
(n=285)
White
(n=785)
p
value
Age, mean (SD) 63.0(6.3) 68.3(6.3) <0.001 Depression, (%) 29.1 26.2 0.35
Female, (%) 77.5 60.9 <0.001 Diabetes, (%) 29.3 17.9 <.001
Geographic Location, (%) <0.001 Hypertension, (%) 83.0 64.9 <.001
Northeast 20 22 Smoking, (%) 48.0 46.7 0.70
Midwest 22.1 25.6 Acetaminophen, (%) 51.4 50.4 0.78
West 7.4 20.1 NSAID, (%) 73.7 77.3 0.25
South 50.5 32.2 Stronger pain medication, (%) 43.3 24.0 <0.001
Education, (%) <0.001 Body Mass Index, (%) <0.001
≤High school 32.0 12.3   < 30 (kg/m2) 31.6 50.1
  >High school 68.0 87.7   ≥30 (kg/m2) 68.4 49.9
Income, (%) <0.001 WOMAC pain, mean (SD) 44.8(20.5) 32.4(16.0) <0.001
<50,000 64.2 34.8 44.9(20.9) 32.2(17.8) <0.001
≥50,000 27.7 54.5 WOMAC function, mean (SD)
Baseline TKR 57 (20.0) 155 (19.8) 0.93 Physical Activity, ≥ 2 met hours/week, (%) 69.8 76.4 0.03

SD; standard deviation, NSAID; non steroidal anti-inflammatory drugs, WOMAC; Western Ontario and McMaster’s 0–100 (100 worse), Stronger pain medication; morphine, propoxyphene, codeine, oxycodone, hydrocodone, tramadol, butalbital/acetaminophen/caffeine, amitryptiline, gabapentin.